A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
Lodosyn
Class :
anti-parkinsonism and Decarboxylase Inhibitors
Brand Name :
No Data Available.
Synonyms :
Lodosyn
Class :
anti-parkinsonism and Decarboxylase Inhibitors
Dosage Forms & Strengths
Tablet
25 mg
carbidopa-levodopa treatment with additional carbidopa:
Initial dose: 25 mg orally once a day
Maintenance dose: additionally, 12.5 mg or 25 mg once a day
The duration of therapy is 200 mg orally per day
titration of carbidopa and levodopa:
Initial dose: 25 mg orally 3 to 4 times a day, levodopa given at the same time
The duration of therapy is 200 mg orally per day
the excretion rate of oxybenzone may be decreased by carbidopa, leading to increased serum levels of oxybenzone
may decrease the serum concentration and decrease in the efficacy
may decrease the therapeutic effect when combined with carbidopa
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
carbidopa concentrations serum could be reduced by spiramycin
carbidopa has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
carbidopa leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefpirome leads to a reduction in the rate of excretion of carbidopa which leads to increased level of serum
carbidopa leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
carbidopa leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
carbidopa leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
carbidopa leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
carbidopa leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
carbidopa: it may increase the risk or severity of CNS depression
carbidopa: it may increase the risk or severity of CNS depression
carbidopa: it may increase the risk or severity of CNS depression
carbidopa: it may increase the risk or severity of CNS depression
carbidopa: it may increase the risk or severity of CNS depression
carbidopa: it may decrease the excretion rate of moxisylyte
carbidopa: it may decrease the excretion rate of metheglobinemia associated agents
carbidopa: it may decrease the excretion rate of metheglobinemia associated agents
carbidopa: it may decrease the excretion rate of metheglobinemia associated agents
carbidopa: it may decrease the excretion rate of metheglobinemia associated agents
carbidopa: it may decrease the excretion rate of metheglobinemia associated agents
carbidopa may decrease the excretion rate of almasilate, leading to higher serum levels
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
the effects of amiloride may be increased by carbidopa
Monitor when these drugs are used concomitantly
the rate of excretion of inositol may be reduced
indobufen: it may decrease the excretion rate of carbidopa
carbidopa might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
Adverse drug reactions:
Frequency not defined:
Agitation
Bruxism
Confusion
Dementia
depression with or without development of suicidal tendencies
Convulsions
Dizziness
burning sensation of the tongue
constipation
Pregnancy warnings:
AU TGA pregnancy category: B3
US FDA pregnancy category: C
Breastfeeding warnings:
The release of the drug into the human breastmilk is known
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: carbidopa
Pronounced: KAR-bi-DOE-pa
Why do we use carbidopa?
carbidopa is an anti-parkinsonism drug belonging to the subclass Decarboxylase Inhibitors used to treat Parkinson’s disease. Carbidopa together taken with a drug levodopa to be effective.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
